Hébert: It's time to stop pharma-driven 'free lunch' approach

Share this article:
The Canadian Medical Association Journal ran an editorial excoriating industry-funded education, which editor-in-chief Dr. Paul Hébert said “embellishes the positive elements of studies and downplays the adverse effects.” “It is time to stop the pharma-driven ‘free-lunch' approach” Hébert concluded.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.